Back to Search
Start Over
Risk factors and treatment of refractory anaphylaxis - a review of case reports.
- Source :
-
Expert review of clinical immunology [Expert Rev Clin Immunol] 2018 Apr; Vol. 14 (4), pp. 307-314. Date of Electronic Publication: 2018 Mar 30. - Publication Year :
- 2018
-
Abstract
- Introduction: Patients experiencing anaphylaxis who do not recover after treatment with intramuscular adrenaline are regarded as suffering from refractory anaphylaxis. The incidence of refractory anaphylaxis is estimated to range between 3-5% of anaphylaxis cases. The risk factors for refractory anaphylaxis are unknown. Areas covered: In the present analysis, we aimed to evaluate the management and risk factors of refractory anaphylaxis to highlight possible clinical implications for updating current management algorithms. Expert commentary: According to international guidelines, adrenaline given through the intramuscular (i.m.) route is a rapid and safe treatment but may be insufficient. Therefore, defined standardized treatment protocols for such cases of refractory anaphylaxis are needed to optimize the treatment. Point-of-care diagnostics may enable doctors to identify patients experiencing severe, refractory anaphylaxis early in order to initiate intensified critical care treatment.
Details
- Language :
- English
- ISSN :
- 1744-8409
- Volume :
- 14
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Expert review of clinical immunology
- Publication Type :
- Academic Journal
- Accession number :
- 29513116
- Full Text :
- https://doi.org/10.1080/1744666X.2018.1450140